Generated by AI
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on rare and orphan diseases, with particular strength in liver and bile-acid related disorders. The company develops and commercializes approved medicines and investigational therapies designed for patients with serious conditions that have limited treatment options. Its commercial portfolio includes treatments for Alagille syndrome, progressive familial intrahepatic cholestasis, bile-acid synthesis disorders, and cerebrotendinous xanthomatosis, supported by a pipeline of additional rare-disease programs. Mirum operates as a specialty rare-disease company, combining drug development, regulatory expertise, and patient-support capabilities to serve children, adults, and families affected by complex genetic and metabolic conditions. Headquartered in Foster City, California, Mirum Pharmaceuticals plays a focused role in the global rare-disease market by bringing targeted therapies to highly specialized clinical settings.
Website989 East Hillsdale Boulevard
Foster City, CA, 94404
United States
The latest articles about MIRM.
Summary of Oct 12's posts. Generated by AI.
Summary of Jul 8's posts. Generated by AI.
Summary of Oct 12's posts. Generated by AI.
Investors talking about MIRM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.